A groundbreaking study has revealed a new autism therapy that has shown significant promise in mouse models, particularly in adult mice. By blocking the glycine transporter SLC6A20, researchers were able to improve social, communication, and repetitive behaviors, offering new hope for potential treatments.
Key Insights
The treatment's mechanism involves improving brain signaling, which in turn enhances behaviors associated with autism in mouse models. Notably, the therapy demonstrated lasting effects in adult mice, suggesting that the brain may remain treatable later in life. Furthermore, its effectiveness in human brain organoids indicates a potential pathway for human application, opening up new avenues for research into autism therapies.
